Rethink Research Competition Needs Your Vote
The Rethink Research Competition has opened voting for its People’s Choice Award.
The Rethink Research Competition has opened voting for its People’s Choice Award. As industry is aware, recruiting patients for clinical research studies is getting harder and harder every year. The Rethink Research Competition is designed to help industry rebrand itself, similar to what the milk industry did in the 1980’s with its “Got Milk?” campaign.
The four following companies have contributed their ideas for a campaign to help this endeavor: ClinEdge, DAC Patient Recruitment Services, MMG and The Patient Recruiting Agency. To vote for your favorite campaign there is a short version and a long version.
Voting closes on September 30. The winners will be announced at MAGI’s Clinical Research Conference in San Diego, October 11-14, 2015.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
